We look at whether payers are willing to pay for innovative gene therapies & CAR-Ts and the impact o...
Read moreOur Market Access Analysts discuss the proposed changes to CAR-T reimbursement in the US and conside...
Read moreDigital therapeutics: a growing market The year is 2008 and Apple have just added a new category to ...
Read moreIntroduction Digital therapeutics (DTx) or digital health technologies (DHTs) are defined as product...
Read moreOur Market Access analysts summarise the EUnetHTA draft scoping process and provide considerations a...
Read moreIntroduction Market Access is critical to commercial success, so the whole organisation needs to be ...
Read moreIntroduction Market access is a constantly developing field with regular updates across various coun...
Read moreIntroduction Payer negotiations can be the most challenging situations that market access teams enco...
Read moreThe EUNetHTA recently published its draft scoping guidance which outlines how the contrasting decisi...
Read moreEUnetHTA and the EU Joint HTA Process EUnetHTA was established in 2006 to facilitate information sha...
Read more